- Home
- LXRX vs CRVS Comparison
LXRX vs CRVS Comparison
Compare LXRX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- CRVS
- Stock Information
- Founded
- LXRX 1995
- CRVS 2014
- Country
- LXRX United States
- CRVS United States
- Employees
- LXRX N/A
- CRVS N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- CRVS Health Care
- Exchange
- LXRX Nasdaq
- CRVS Nasdaq
- Market Cap
- LXRX 283.7M
- CRVS 335.1M
- IPO Year
- LXRX 2000
- CRVS 2016
- Fundamental
- Price
- LXRX $0.71
- CRVS $4.19
- Analyst Decision
- LXRX Buy
- CRVS Strong Buy
- Analyst Count
- LXRX 2
- CRVS 5
- Target Price
- LXRX $4.00
- CRVS $12.38
- AVG Volume (30 Days)
- LXRX 4.1M
- CRVS 383.9K
- Earning Date
- LXRX 03-10-2025
- CRVS 03-18-2025
- Dividend Yield
- LXRX N/A
- CRVS N/A
- EPS Growth
- LXRX N/A
- CRVS N/A
- EPS
- LXRX N/A
- CRVS N/A
- Revenue
- LXRX $5,229,000.00
- CRVS N/A
- Revenue This Year
- LXRX $842.94
- CRVS N/A
- Revenue Next Year
- LXRX $19.76
- CRVS N/A
- P/E Ratio
- LXRX N/A
- CRVS N/A
- Revenue Growth
- LXRX 886.60
- CRVS N/A
- 52 Week Low
- LXRX $0.62
- CRVS $1.30
- 52 Week High
- LXRX $2.83
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- LXRX 43.33
- CRVS 28.71
- Support Level
- LXRX $0.66
- CRVS $4.60
- Resistance Level
- LXRX $0.97
- CRVS $5.19
- Average True Range (ATR)
- LXRX 0.07
- CRVS 0.30
- MACD
- LXRX -0.00
- CRVS -0.06
- Stochastic Oscillator
- LXRX 16.13
- CRVS 2.01
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).